| __timestamp | Novavax, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 79435000 | 19586000 |
| Thursday, January 1, 2015 | 162644000 | 29135000 |
| Friday, January 1, 2016 | 237939000 | 42791000 |
| Sunday, January 1, 2017 | 168435000 | 49577000 |
| Monday, January 1, 2018 | 173797000 | 89209000 |
| Tuesday, January 1, 2019 | 113842000 | 69099000 |
| Wednesday, January 1, 2020 | 747027000 | 75961000 |
| Friday, January 1, 2021 | 2534508000 | 90467000 |
| Saturday, January 1, 2022 | 1235278000 | 74552000 |
| Sunday, January 1, 2023 | 737502000 | 91593000 |
Unleashing insights
In the competitive world of biotechnology, investment in research and development (R&D) is crucial for staying ahead. Over the past decade, Novavax, Inc. and Supernus Pharmaceuticals, Inc. have shown contrasting approaches to innovation. From 2014 to 2023, Novavax's R&D spending surged by over 900%, peaking in 2021 with a staggering 2.5 billion dollars. This reflects their aggressive pursuit of cutting-edge vaccine technology, especially during the COVID-19 pandemic. In contrast, Supernus Pharmaceuticals maintained a steady increase, with a 368% rise in R&D expenses, reaching its highest in 2023. This consistent growth underscores their focus on developing treatments for central nervous system disorders. While Novavax's strategy is marked by rapid scaling, Supernus opts for a more measured approach. These differing strategies highlight the diverse paths companies can take in the quest for innovation.
Novartis AG vs Novavax, Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: Gilead Sciences, Inc. and Novavax, Inc.
R&D Insights: How Zoetis Inc. and Supernus Pharmaceuticals, Inc. Allocate Funds
Comparing Innovation Spending: Alnylam Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Limited vs Novavax, Inc.: Strategic Focus on R&D Spending
Viatris Inc. vs Novavax, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Insmed Incorporated and Supernus Pharmaceuticals, Inc.
Alkermes plc vs Supernus Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: Alpine Immune Sciences, Inc. and Supernus Pharmaceuticals, Inc.
R&D Spending Showdown: Alpine Immune Sciences, Inc. vs Novavax, Inc.
Analyzing R&D Budgets: Vericel Corporation vs Supernus Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Mesoblast Limited and Novavax, Inc.